A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria

Abstract

Background

Chronic urticaria (CU) is a prevalent dermatologic disease that negatively affects life, current therapies remain suboptimal. Hence, there is an urgent need to identify effective and safe treatment.

Objective

Assess the efficacy and safety of compound glycyrrhizin (CG) combined with second-generation nonsedated antihistamine for the treatment of CU.

Methods

Nine databases were queried to screen RCTs related. Two reviewers independently assessed the risk of bias using Cochrane Collaboration. Primary objective was the total efficiency rate, while secondary was rate of recurrence, adverse events, and cure. Statistical analyses using Review Manager 5.4 and Stata17.

Results

Twenty-four RCTs were identified. Significant differences were noted in rate of total efficiency (n = 2649, RR = 1.36, 95%CI:1.30–1.43, p < 0.00001), cure (n = 2649, RR = 1.54, 95%CI:1.42–1.66, p < 0.00001) and recurrence (n = 446, RR = 0.34, 95%CI:0.20–0.58, p < 0.00001) between the combination of CG with second-generation non-sedated antihistamine and antihistamine monotherapy. Contrastingly, adverse events rate (n = 2317, RR = 0.76, 95% CI:0.59–0.97, p = 0.03) was comparable between the two groups. Our results indicated that CG combined with second-generation non-sedated antihistamine could significantly mitigate the symptoms in CU compared with antihistamine monotherapy. No serious adverse events were reported.

Conclusions

CG combined with second-generation nonsedated antihistamine is effective for CU. Nevertheless, higher-quality studies are warranted to validate our results.

Keywords:

• Chronic urticaria
• compound glycyrrhizin tablet
• compound glycyrrhizin capsule
• compound glycyrrhizin injection
• antihistamine. meta-analysis

Disclosure statement

The authors declare that there are no conflicts of interest regarding the publication of this article.

Supplementary data description

Supplementary data to this article (Table 1 Studies included/Table S1 PRISMA_2020_checklist/Table S2 Search strategy) has been submitted as a supplementary material.

Additional information

Funding

This research was supported by ‘13th Five-Year Plan’ National Key Research and Development Plan ‘Modernization Research of Traditional Chinese Medicine’ Key project (Project number: SQ2017YFC170007), ‘International Cooperative Research on the Efficacy Evaluation of Acupuncture and Moxibustion Superior Diseases’ the fifth project ‘Acupuncture and Moxibustion Treatment of Chronic Urticaria’ (project number: 2017YFC1703605), Sichuan Provincial Administration of Traditional Chinese Medicine Science and Technology Research Special (Project number: 2021MS320)